SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 > View All News All News Upcoming Events August 25, 2026 Half Year Results 2026 (unaudited) > View All Events All Events Latest Presentation May 12, 2026 Corporate Presentation – Q1 financials, May 2026 March 12, 2026 Corporate Presentation – Full Year 2025 Financials February 2, 2026 MP0712: First patient imaging and dosimetry data presented at TWC 2026, Clinical Outlook > View All Presentations All Presentations Latest Financial Documents May 12, 2026 Q1 Financial Statement 2026 April 16, 2026 Molecular Partners statement regarding Passive Foreign Investment Company status March 12, 2026 Annual Report FY2025 > View All Reports All Annual Report Seth Lewis,EVP Corporate FinanceContact SethSTAY INFORMEDSubscribe to email alerts of your choosingSUBSCRIBEInstitutional investors: REQUEST 1-1 / CALLpowered by schedulR
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
February 2, 2026 MP0712: First patient imaging and dosimetry data presented at TWC 2026, Clinical Outlook
